ATP binding cassette subfamily G member 2 (JR blood group)Genealiases: ABC15 · ABCP · BCRP · BMDP · CD338 · CDw338
Q-omics provides the consensus-scored ABCG2 profile across patient tissues and cancer cell-line models. ABCG2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABCG2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ABCG2 RNA expression shows 22,505 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, COAD, and CCRCC as cancer lineages where ABCG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCG2 survival associations across molecular data types. ABCG2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCG2 RNA expression–survival associations across cancer types. High ABCG2 expression shows unfavorable associations in STAD, COAD and HNSC, but favorable associations in KIRC, THCA and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABCG2 RNA expression.
This table summarizes ABCG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ABCG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCG2 shows lower tumor expression in COAD, KIRP, LUAD, UCEC, LUSC and KICH. The COAD box plot shows higher ABCG2 RNA expression in normal versus tumor tissue (log2 FC = −4.324, t-test p < 0.001).
This table shows molecular features associated with ABCG2 in patient tissues and cancer cell lines. In patient samples, ABCG2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
